These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
131 related articles for article (PubMed ID: 37801632)
1. Antibody-Mediated Nanodrug of Proteasome Inhibitor Carfilzomib Boosts the Treatment of Multiple Myeloma. Chen R; Yang J; Mao Y; Zhao X; Cheng R; Deng C; Zhong Z Biomacromolecules; 2023 Nov; 24(11):5371-5380. PubMed ID: 37801632 [TBL] [Abstract][Full Text] [Related]
2. A6 Peptide-Tagged Core-Disulfide-Cross-Linked Micelles for Targeted Delivery of Proteasome Inhibitor Carfilzomib to Multiple Myeloma In Vivo. Zhang C; Wang X; Cheng R; Zhong Z Biomacromolecules; 2020 Jun; 21(6):2049-2059. PubMed ID: 32338875 [TBL] [Abstract][Full Text] [Related]
3. Polymer micelle formulations of proteasome inhibitor carfilzomib for improved metabolic stability and anticancer efficacy in human multiple myeloma and lung cancer cell lines. Ao L; Reichel D; Hu D; Jeong H; Kim KB; Bae Y; Lee W J Pharmacol Exp Ther; 2015 Nov; 355(2):168-73. PubMed ID: 26311812 [TBL] [Abstract][Full Text] [Related]
4. Polymer micelle formulation for the proteasome inhibitor drug carfilzomib: Anticancer efficacy and pharmacokinetic studies in mice. Park JE; Chun SE; Reichel D; Min JS; Lee SC; Han S; Ryoo G; Oh Y; Park SH; Ryu HM; Kim KB; Lee HY; Bae SK; Bae Y; Lee W PLoS One; 2017; 12(3):e0173247. PubMed ID: 28273121 [TBL] [Abstract][Full Text] [Related]
5. Curcumin ameliorates the in vitro efficacy of carfilzomib in human multiple myeloma U266 cells targeting p53 and NF-κB pathways. Allegra A; Speciale A; Molonia MS; Guglielmo L; Musolino C; Ferlazzo G; Costa G; Saija A; Cimino F Toxicol In Vitro; 2018 Mar; 47():186-194. PubMed ID: 29223572 [TBL] [Abstract][Full Text] [Related]
6. Milder degenerative effects of Carfilzomib vs. Bortezomib in the Drosophila model: a link to clinical adverse events. Tsakiri EN; Terpos E; Papanagnou ED; Kastritis E; Brieudes V; Halabalaki M; Bagratuni T; Florea BI; Overkleeft HS; Scorrano L; Skaltsounis AL; Dimopoulos MA; Trougakos IP Sci Rep; 2017 Dec; 7(1):17802. PubMed ID: 29259189 [TBL] [Abstract][Full Text] [Related]
7. Carfilzomib experience in relapsed/refractory multiple myeloma: a single-center experience. Uysal A; Akad Soyer N; Özkan M; Şahin F; Vural F; Töbü M; Tombuloğlu M; Saydam G Turk J Med Sci; 2018 Feb; 48(1):80-83. PubMed ID: 29479960 [TBL] [Abstract][Full Text] [Related]
8. Carfilzomib. Engelhardt M; Szymaniak-Vits M; Ajayi S; Dold SM; Müller SJ; Scheubeck S; Wäsch R Recent Results Cancer Res; 2018; 212():265-283. PubMed ID: 30069635 [TBL] [Abstract][Full Text] [Related]
9. Carfilzomib-Loaded Ternary Polypeptide Nanoparticles Stabilized by Polycationic Complexation. Agbana P; Park JE; Rychahou P; Kim KB; Bae Y J Pharm Sci; 2024 Mar; 113(3):711-717. PubMed ID: 37673172 [TBL] [Abstract][Full Text] [Related]
10. Carfilzomib enhances natural killer cell-mediated lysis of myeloma linked with decreasing expression of HLA class I. Yang G; Gao M; Zhang Y; Kong Y; Gao L; Tao Y; Han Y; Wu H; Meng X; Xu H; Zhan F; Wu X; Shi J Oncotarget; 2015 Sep; 6(29):26982-94. PubMed ID: 26323098 [TBL] [Abstract][Full Text] [Related]
12. Carfilzomib Induced Tumor Lysis Syndrome and Other Adverse Events. Sandy EB; Weerasinghe C; Terjanian T J Pharm Pract; 2020 Apr; 33(2):213-216. PubMed ID: 30278813 [TBL] [Abstract][Full Text] [Related]
13. Hyaluronic acid shell and disulfide-crosslinked core micelles for in vivo targeted delivery of bortezomib for the treatment of multiple myeloma. Gu Z; Wang X; Cheng R; Cheng L; Zhong Z Acta Biomater; 2018 Oct; 80():288-295. PubMed ID: 30240956 [TBL] [Abstract][Full Text] [Related]
14. Investigating the Vascular Toxicity Outcomes of the Irreversible Proteasome Inhibitor Carfilzomib. Efentakis P; Doerschmann H; Witzler C; Siemer S; Nikolaou PE; Kastritis E; Stauber R; Dimopoulos MA; Wenzel P; Andreadou I; Terpos E Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32707866 [TBL] [Abstract][Full Text] [Related]
15. Daratumumab Immunopolymersome-Enabled Safe and CD38-Targeted Chemotherapy and Depletion of Multiple Myeloma. Yu N; Zhang Y; Li J; Gu W; Yue S; Li B; Meng F; Sun H; Haag R; Yuan J; Zhong Z Adv Mater; 2021 Oct; 33(39):e2007787. PubMed ID: 34369013 [TBL] [Abstract][Full Text] [Related]
16. SUMOylation inhibition overcomes proteasome inhibitor resistance in multiple myeloma. Heynen GJJE; Baumgartner F; Heider M; Patra U; Holz M; Braune J; Kaiser M; Schäffer I; Bamopoulos SA; Ramberger E; Murgai A; Ng YLD; Demel UM; Laue D; Liebig S; Krüger J; Janz M; Nogai A; Schick M; Mertins P; Müller S; Bassermann F; Krönke J; Keller U; Wirth M Blood Adv; 2023 Feb; 7(4):469-481. PubMed ID: 35917568 [TBL] [Abstract][Full Text] [Related]
17. Carfilzomib demonstrates broad anti-tumor activity in pre-clinical non-small cell and small cell lung cancer models. Baker AF; Hanke NT; Sands BJ; Carbajal L; Anderl JL; Garland LL J Exp Clin Cancer Res; 2014 Dec; 33(1):111. PubMed ID: 25612802 [TBL] [Abstract][Full Text] [Related]
18. Efficacy and toxicity profile of carfilzomib based regimens for treatment of multiple myeloma: A systematic review. Mushtaq A; Kapoor V; Latif A; Iftikhar A; Zahid U; McBride A; Abraham I; Riaz IB; Anwer F Crit Rev Oncol Hematol; 2018 May; 125():1-11. PubMed ID: 29650268 [TBL] [Abstract][Full Text] [Related]
19. The novel proteasome inhibitor carfilzomib induces cell cycle arrest, apoptosis and potentiates the anti-tumour activity of chemotherapy in rituximab-resistant lymphoma. Gu JJ; Hernandez-Ilizaliturri FJ; Kaufman GP; Czuczman NM; Mavis C; Skitzki JJ; Czuczman MS Br J Haematol; 2013 Sep; 162(5):657-69. PubMed ID: 23826755 [TBL] [Abstract][Full Text] [Related]
20. Carfilzomib Delivery by Quinic Acid-Conjugated Nanoparticles: Discrepancy Between Tumoral Drug Accumulation and Anticancer Efficacy in a Murine 4T1 Orthotopic Breast Cancer Model. Jun Y; Xu J; Kim H; Park JE; Jeong YS; Min JS; Yoon N; Choi JY; Yoo J; Bae SK; Chung SJ; Yeo Y; Lee W J Pharm Sci; 2020 Apr; 109(4):1615-1622. PubMed ID: 31945310 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]